心电图701什么病针对多种血液癌症，多款创新疗法展现积极临床试验进展…… ｜ 一周盘点

[1] Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/07/3201111/0/en/Molecular-Partners-Presents-Updated-Data-from-Ongoing-Phase-1-2a-Trial-of-MP0533-in-AML-at-ASH-Annual-Meeting.html

[2] Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition. Retrieved December 12, 2025, from https://www.prnewswire.com/news-releases/rigel-presents-updated-data-from-the-ongoing-phase-1b-study-evaluating-r289-in-patients-with-lower-risk-mds-at-the-67th-ash-annual-meeting-and-exposition-302634716.html

[3] Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/06/3201044/0/en/Beam-Therapeutics-Reports-Updated-Data-from-BEACON-Phase-1-2-Trial-of-ristoglogene-autogetemcel-risto-cel-Highlighting-Durable-Differentiated-Profile-in-Sickle-Cell-Disease-SCD-at-.html

[4] Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/06/3201099/0/en/Fulcrum-Therapeutics-Announces-Positive-Initial-Results-from-the-20-mg-Dose-Cohort-of-the-Phase-1b-PIONEER-Trial-of-Pociredir-in-Sickle-Cell-Disease-at-the-67th-American-Society-of.html

[5] TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/06/3201100/0/en/TScan-Therapeutics-Announces-Positive-Updated-Data-from-the-ALLOHA-Phase-1-Heme-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html

[6] Korean gene therapy RZ-001 reports encouraging phase 1 data in brain cancer. Retrieved December 12, 2025, from https://www.koreabiomed.com/news/articleView.html?idxno=29888

[7] Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome. Retrieved December 12, 2025, from https://encoded.com/press-releases/encoded-therapeutics-presents-positive-interim-efficacy-data-from-initial-dose-levels-of-phase-1-2-trials-evaluating-etx101-gene-therapy-in-dravet-syndrome/

[8] PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Retrieved December 12, 2025, from https://www.businesswire.com/news/home/20251205523069/en/PureTechs-Founded-Entity-Gallop-Oncology-Announces-Positive-Initial-Topline-Data-from-Phase-1b-Trial-of-LYT-200-in-RelapsedRefractory-Acute-Myeloid-Leukemia-and-High-Risk-Myelodysplastic-Syndrome

[9] Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/08/3201397/0/en/Kymera-Therapeutics-Announces-Positive-Results-from-BroADen-Phase-1b-Clinical-Trial-of-KT-621-a-First-in-Class-Oral-STAT6-Degrader-in-Patients-with-Moderate-to-Severe-Atopic-Dermat.html

[10] Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/08/3201967/16259/en/Assembly-Biosciences-Reports-Positive-Interim-Results-from-Phase-1b-Clinical-Studies-of-Long-Acting-Helicase-Primase-Inhibitor-Candidates-ABI-1179-and-ABI-5366-Showing-Reductions-i.html

[11] Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting. Retrieved December 12, 2025, from https://ir.ternspharma.com/news-releases/news-release-details/terns-highlights-additional-positive-phase-1-clinical-data

[12] Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html

[13] Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/08/3201474/24675/en/Fate-Therapeutics-Presents-Updated-Phase-1-Clinical-Data-of-FT819-Off-the-shelf-CAR-T-cell-Product-Candidate-for-Systemic-Lupus-Erythematosus-and-Preclinical-Advances-in-Next-Gener.html

[14] Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/08/3201434/0/en/Positive-Phase-1b-2-Results-from-Ongoing-REC-4881-TUPELO-Trial-Demonstrate-Rapid-and-Durable-Reductions-in-Polyp-Burden-in-Familial-Adenomatous-Polyposis-FAP-at-25-Weeks.html

[15] Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting. Retrieved December 12, 2025, from https://www.businesswire.com/news/home/20251205981362/en/Star-Therapeutics-Presents-Interim-Data-from-Phase-12-Multidose-Study-of-VGA039-in-Von-Willebrand-Disease-Demonstrating-Substantial-Bleed-Reductions-in-All-Patients-at-ASH-Annual-Meeting 

[16] Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025. Retrieved December 12, 2025, from https://www.businesswire.com/news/home/20251206612260/en/Kites-Next-Generation-Bicistronic-CAR-T-Cell-Therapies-Show-Encouraging-Phase-1-Results-in-RelapsedRefractory-B-Cell-Lymphoma-in-New-Data-at-ASH-2025

[17] Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/09/3202225/0/en/Senti-Bio-Announces-Updated-SENTI-202-Clinical-Data-from-Ongoing-Phase-1-Trial-in-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-Patients-Demonstrating-Deep-MRD-Negative-Durable-Com.html

[18] ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/09/3202198/0/en/ONL-Therapeutics-Announces-Publication-of-Data-from-Phase-1b-Study-of-Xelafaslatide-an-Investigational-Therapy-for-Geographic-Atrophy-in-Ophthalmology-Science.html

[19] Aleta Biotherapeutics and Cancer Research UK Announce Promising Phase I/II Data from ALETA-001 Clinical Trial for Patients With Relapsed/Refractory B-Cell Malignancies Previously Treated with CD19 CAR T-Cell Therapy. Retrieved December 12, 2025, from https://www.businesswire.com/news/home/20251208038512/en/Aleta-Biotherapeutics-and-Cancer-Research-UK-Announce-Promising-Phase-III-Data-from-ALETA-001-Clinical-Trial-for-Patients-With-RelapsedRefractory-B-Cell-Malignancies-Previously-Treated-with-CD19-CAR-T-Cell-Therapy

[20] Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting. Retrieved December 12, 2025, from https://abcuro.com/uncategorized/abcuro-presents-interim-phase-1-data-evaluating-ulviprubart-in-patients-with-t-cell-large-granular-lymphocytic-leukemia-at-the-67th-american-society-of-hematology-annual-meeting/

[21] Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/10/3202943/0/en/Igyxos-Biotherapeutics-Announces-Positive-Results-from-Phase-1-Trial-of-IGX12-its-First-in-Class-Monoclonal-Antibody-for-the-Treatment-of-Male-and-Female-Infertility.html

[22] NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/10/3203528/0/en/NovaBridge-Presents-Positive-Ragistomig-Phase-1-Dose-Expansion-Data-at-ESMO-IO.html

[23] Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis. Retrieved December 12, 2025, from https://enterprisetherapeutics.com/enterprise-therapeutics-publishes-results-of-phase-1-study-of-etd001-a-novel-inhaled-enac-blocker-for-treatment-of-cystic-fibrosis-in-the-journal-of-cystic-fibrosis/

[24] Results from Phase 1 Multiple-Dose Study of PT00114. Retrieved December 12, 2025, from https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=6&b=2612&ID=160340&m=rl&g=1834

[25] ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/11/3203848/0/en/ImmuneWalk-Therapeutics-Announces-Positive-Results-from-Phase-1-SAD-MAD-Study-of-IW-601-a-First-In-Class-Therapeutic-with-Broad-Potential-in-Inflammatory-and-Autoimmune-Diseases.html

[26] Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/11/3203762/0/en/Corbus-Pharmaceuticals-Reports-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-Demonstrating-Favorable-Safety-Profile-and-Emerging-Evi.html

[27] Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC. Retrieved December 12, 2025, from https://www.globenewswire.com/news-release/2025/12/11/3204284/0/en/Tenaya-Therapeutics-Reports-Positive-Interim-Data-from-Cohort-1-of-RIDGE-1-Phase-1b-2-Clinical-Trial-of-TN-401-Gene-Therapy-for-Adults-with-PKP2-associated-ARVC.html